Development

PharmaForce is an industry leader in rapid, high quality sterile drug product development. Our cGMP research & development facilities are capable of performing a wide range of drug development activities, including active pharmaceutical ingredient qualification, analytical methods development and validation, product stability storage and monitoring, analytical testing and drug product dossier development and submission.

Our sterile parenteral, ophthalmic, otic and nasal delivery formats accommodate aqueous solutions, suspensions and lyophilized dosage forms.

PharmaForce’s diverse development capacity is capable of processing over 30 drug product development candidates annually, including cytotoxic and other highly potent compounds. We develop drug products across a wide therapeutic range including vasodilators, anti-arrythmic agents, CNS agents, anti-infectives, immuno-suppressants, antifungals, beta-blockers and antivirals.

Manufacturing

PharmaForce manufactures sterile finished dosage pharmaceutical products in its state-of-the-art facility located in Hilliard, Ohio, a suburb of Columbus. The facility was commissioned in November 2005.

The plant provides manufacturing support for the commercialization of sterile pharmaceutical products targeted for U.S. and global markets. The new facility enables PharmaForce to ensure an uninterrupted source of commercial supply while also providing advanced development and clinical manufacturing opportunities. All batches are manufactured in accordance with current Good Manufacturing Practices (cGMPs).

Clinical manufacturing activities can support Pre-IND and IND Phase I-III activities. All clinical batches use the same documentation, equipment, and personnel as our commercial production batches.

Each of our facilities offers unique sterile manufacturing capabilities. We offer a broad range of batch sizes with fill volumes from 0.5 mL to 100 mL. Product can be packaged in glass (vials, ampules, and bottles) and plastic (vials and bottles).